diphenylcyclopropenone has been researched along with Skin Neoplasms in 25 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (8.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (16.00) | 29.6817 |
2010's | 14 (56.00) | 24.3611 |
2020's | 5 (20.00) | 2.80 |
Authors | Studies |
---|---|
Agarwal, A; Estrada, Y; Gulati, N; Han, J; Krueger, JG; Luu, Y; Owji, S; Poplausky, D; Ungar, J; Yassky, D; Young, JN | 1 |
Dwyer, L; Frew, JW; Menzies, AM; Pham, JP; Phan, K | 1 |
Garioch, J; Lo, MC; Moncrieff, MD | 1 |
Bertolli, E; Calsavara, VF; Duprat Neto, JP; Lôbo, MM; Lopes Pinto, CA; Ricci, BV | 1 |
Abadir, W; Alavi, N; Look Hong, NJ; Nadler, A; Wright, FC | 1 |
Read, T; Schaider, H; Smithers, BM; Soyer, HP; Tan, J; Wagels, M; Webber, S | 1 |
Read, T; Schaider, H; Smithers, BM; Soyer, HP; Thomas, J; Wagels, M; Webber, S | 1 |
Bertolli, E; Duprat Neto, JP; Gibbons, IL; Macedo, MP; Pinto, CAL; Sonagli, M | 1 |
Baum, CL; Jakub, JW; Veverka, KK | 1 |
Bullen, A; Byrom, L; Khosrotehrani, K; Polcz, M; Rowe, CJ; Soyer, HP | 1 |
Damian, DL; Saw, RP; Thompson, JF | 1 |
Fawcett, JM; Kennedy, CT; Newell, EL | 1 |
Fadhil, M; Garioch, J; Moncrieff, M | 1 |
Aiba, S; Fujimura, T; Furudate, S; Haga, T; Hashimoto, A; Kakizaki, A; Kambayashi, Y | 1 |
Carvajal, RD; Gulati, N; Krueger, JG; Postow, MA; Wolchok, JD | 1 |
Abadir, W; Look Hong, NJ; Petrella, TM; Wright, FC; Yeung, C | 1 |
Damian, DL; Saw, RP; Shannon, KF; Thompson, JF | 1 |
Damian, DL; Levis, WR; Martiniuk, F; Scolyer, RA; Tchou-Wong, KM; Thompson, JF | 1 |
Damian, DL; Saw, RPM | 1 |
Damian, DL; Thompson, JF | 2 |
Hengge, UR; Meykadeh, N | 1 |
Sterry, W; Trefzer, U | 1 |
Harland, CC; Saihan, EM | 1 |
Mayerhausen, W; Remy, W | 1 |
3 review(s) available for diphenylcyclopropenone and Skin Neoplasms
Article | Year |
---|---|
Efficacy of topical diphencyprone for melanoma in-transit metastases: a systematic review and meta-analysis.
Topics: Cyclopropanes; Humans; Melanoma; Skin Neoplasms | 2023 |
Response rates of cutaneous melanoma metastases to diphencyprone: A meta-analysis.
Topics: Administration, Cutaneous; Cyclopropanes; Haptens; Humans; Melanoma; Skin; Skin Neoplasms; Treatment Outcome | 2020 |
Topical immunotherapy with diphencyprone for in transit and cutaneously metastatic melanoma.
Topics: Administration, Topical; Animals; Cyclopropanes; Dermatitis, Contact; Humans; Immunotherapy; Melanoma; Neoplasm Metastasis; Skin Neoplasms | 2014 |
1 trial(s) available for diphenylcyclopropenone and Skin Neoplasms
Article | Year |
---|---|
Protocol for the TIDAL Melanoma Study: topical imiquimod or diphenylcyclopropenone for the management of cutaneous in-transit melanoma metastases-a phase II, single centre, randomised, pilot study.
Topics: Administration, Topical; Adolescent; Adult; Aged; Aged, 80 and over; Aminoquinolines; Antineoplastic Agents; Clinical Protocols; Cyclopropanes; Female; Humans; Imiquimod; Immunotherapy; Male; Melanoma; Middle Aged; Pilot Projects; Remission Induction; Research Design; Skin Neoplasms; Treatment Outcome; Young Adult | 2017 |
21 other study(ies) available for diphenylcyclopropenone and Skin Neoplasms
Article | Year |
---|---|
Proteomic profiling of a patient with cutaneous melanoma metastasis regression following topical contact sensitizer diphencyprone and immune checkpoint inhibitor treatment.
Topics: Humans; Immune Checkpoint Inhibitors; Immunotherapy; Melanoma; Melanoma, Cutaneous Malignant; Proteomics; Skin Neoplasms | 2022 |
Sequencing in management of in-transit melanoma metastasis: Diphencyprone versus isolate limb infusion.
Topics: Aged; Aged, 80 and over; Chemotherapy, Cancer, Regional Perfusion; Cost of Illness; Cyclopropanes; Disease Progression; Female; Humans; Male; Melanoma; Middle Aged; Retrospective Studies; Skin Neoplasms | 2020 |
Lesional therapies for in-transit melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclopropanes; Female; Follow-Up Studies; Humans; Imiquimod; Injections, Intralesional; Interleukin-2; Male; Melanoma; Middle Aged; Prognosis; Retrospective Studies; Skin Neoplasms; Survival Rate | 2020 |
Diphenylcyclopropenone for the treatment of cutaneous in-transit melanoma metastases - results of a prospective, non-randomized, single-centre study.
Topics: Adult; Aged; Aged, 80 and over; Cyclopropanes; Female; Humans; Male; Melanoma; Middle Aged; Prospective Studies; Skin Neoplasms; Treatment Outcome | 2017 |
Diphencyprone as a therapeutic option in cutaneous metastasis of melanoma. A single-institution experience.
Topics: Administration, Cutaneous; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biopsy; Brazil; Cyclopropanes; Female; Humans; Male; Melanoma; Middle Aged; Skin Neoplasms; Treatment Outcome; Young Adult | 2018 |
Responses to Topical Diphenylcyclopropenone as an Adjunct Treatment for In-Transit Melanoma: A Tertiary Referral Center Experience.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aged; Cyclopropanes; Disease Progression; Female; Haptens; Humans; Immunotherapy; Male; Melanoma; Middle Aged; Neoplastic Cells, Circulating; Retrospective Studies; Skin Neoplasms; Tertiary Care Centers; Treatment Outcome; Tumor Burden | 2018 |
Level of contact hypersensitivity response to diphencyprone and keratinocyte cancer.
Topics: Aged; Cyclopropanes; Dermatitis, Contact; Female; Humans; Immunologic Tests; Keratinocytes; Male; Prospective Studies; Skin Neoplasms | 2019 |
Congenital malignant melanoma and cutaneous metastases treated with diphencyprone.
Topics: Antineoplastic Agents; Cyclopropanes; Humans; Infant; Male; Melanoma; Orbital Neoplasms; Skin Neoplasms; Treatment Outcome | 2016 |
Topical diphencyprone for the treatment of locoregional intralymphatic melanoma metastases of the skin; the 5-year Norwich experience.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Antineoplastic Agents; Cyclopropanes; Disease-Free Survival; Female; Humans; Lymphatic Metastasis; Male; Melanoma; Middle Aged; Prospective Studies; Skin Neoplasms; Treatment Outcome | 2016 |
Contact immunotherapy enhances the therapeutic effects of nivolumab in treating in-transit melanoma: Two cases reports.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Cyclobutanes; Cyclopropanes; Female; Humans; Immunotherapy; Male; Melanoma; Nivolumab; Skin Neoplasms | 2016 |
Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment.
Topics: Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Cyclopropanes; Drug Therapy, Combination; Humans; Male; Melanoma; Skin Neoplasms | 2016 |
Topical immunotherapy with diphencyprone (DPCP) for in-transit and unresectable cutaneous melanoma lesions: an inaugural Canadian series.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Canada; Cyclopropanes; Female; Follow-Up Studies; Humans; Immunization; Immunotherapy; Male; Melanoma; Middle Aged; Quality of Life; Retrospective Studies; Skin; Skin Neoplasms; Treatment Outcome | 2017 |
Topical diphencyprone immunotherapy for cutaneous metastatic melanoma.
Topics: Administration, Cutaneous; Aged; Aged, 80 and over; Antineoplastic Agents; Cyclopropanes; Humans; Male; Melanoma; Neoplasm Recurrence, Local; Skin Neoplasms; Treatment Outcome | 2009 |
TH17 is involved in the remarkable regression of metastatic malignant melanoma to topical diphencyprone.
Topics: Administration, Topical; Aged; Antigens, CD; CTLA-4 Antigen; Cyclopropanes; Haptens; Humans; Interleukin-17; Kruppel-Like Transcription Factors; Male; Melanoma; Ointments; Promyelocytic Leukemia Zinc Finger Protein; Reverse Transcriptase Polymerase Chain Reaction; Scalp; Skin Neoplasms; Th17 Cells | 2010 |
Dramatic regression of cutaneous, nodal, and visceral melanoma metastases.
Topics: Adjuvants, Immunologic; Aged, 80 and over; Anti-Infective Agents, Local; Cyclopropanes; Humans; Immunotherapy; Lung Neoplasms; Lymphatic Metastasis; Male; Melanoma; Silver Sulfadiazine; Skin Neoplasms | 2011 |
Topical diphencyprone immunotherapy for a large primary melanoma on an elderly leg.
Topics: Administration, Cutaneous; Aged, 80 and over; Cyclopropanes; Humans; Immunotherapy; Male; Melanoma; Skin Neoplasms; Treatment Outcome | 2011 |
[Topical immunomodulators in dermatology].
Topics: Adjuvants, Immunologic; Administration, Topical; Adult; Aged; Aged, 80 and over; Aminoquinolines; Asthma; Autoimmune Diseases; Bowen's Disease; Child; Cyclopropanes; Dermatitis, Atopic; Dinitrochlorobenzene; Female; Follow-Up Studies; Herpes Simplex; Humans; Imidazoles; Imiquimod; Immunity, Cellular; Immunocompromised Host; Immunoglobulin A; Immunosuppressive Agents; Lichen Sclerosus et Atrophicus; Male; Molluscum Contagiosum; Papillomavirus Infections; Precancerous Conditions; Skin Diseases; Skin Diseases, Viral; Skin Neoplasms; Tacrolimus; Time Factors; Warts | 2003 |
Topical immunotherapy with diphenylcyclopropenone in combination with DTIC and radiation for cutaneous metastases of melanoma.
Topics: Adjuvants, Immunologic; Administration, Cutaneous; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cyclopropanes; Dacarbazine; Dose Fractionation, Radiation; Follow-Up Studies; Humans; Injections, Intravenous; Male; Melanoma; Radiotherapy, Adjuvant; Skin Neoplasms | 2005 |
Treatment of extensive cutaneous metastatic melanoma with topical diphencyprone.
Topics: Administration, Topical; Aged; Antineoplastic Agents; Cyclopropanes; Humans; Male; Melanoma; Neoplasm Recurrence, Local; Skin Neoplasms | 2007 |
Regression of cutaneous metastatic malignant melanoma with topical diphencyprone and oral cimetidine.
Topics: Administration, Oral; Administration, Topical; Aged; Cimetidine; Cyclopropanes; Drug Administration Schedule; Female; Humans; Melanoma; Skin Neoplasms | 1989 |
[Testing of cellular immune reactivity in melanoma patients with diphenylcyclopropenone in comparison to dinitrochlorobenzol].
Topics: Cyclopropanes; Dinitrochlorobenzene; Humans; Immune Tolerance; Immunity, Cellular; Melanoma; Patch Tests; Skin Neoplasms | 1987 |